Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BOEHRINGER INGELHEIM CORP. NAMES DIGBY BARRIOS PRESIDENT

Executive Summary

BOEHRINGER INGELHEIM CORP. NAMES DIGBY BARRIOS PRESIDENT and CEO, replacing Harvey Sadow, MD, who retired from the company earlier this year. In his new position, Barrios will have principal operating responsibility for Boehringer Ingelheim's total U.S. operations, which include pharmaceuticals, animal health, unit-dose manufacturing and specialty chemicals. Barrios, a former Squibb group VP, is the current president of Boehringer Ingelheim Pharmaceuticals, a job he will retain, as well as exec VP of Boehringer Ingelheim Corp. Of the company's total $500 mil. revenues in the most recent fiscal year, the drug business accounted for about three-fifths, or $320 mil., the firm said. Barrios joined the pharmaceutical unit in 1983 as exec VP and was named an exec VP of the U.S. parent in 1986. Despite his retirement from day-to-day operations, Sadow will continue as chairman of both Boehringer Ingelheim Corp. and Boehringer Ingelheim Pharmaceuticals, the company noted in a March 15 press release. Other announced appointments include Werner Gerstenberg to exec VP-Boehringer Ingelheim Corp., who continues as senior VP-finance and administration and treasurer of the pharmaceutical operation, and Kevin Reddington to VP-mergers & acquisitions of Boehringer Ingelheim Corp. Reddington was most recently VP-finance of the drug unit.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS013361

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel